Oncolytics Biotech Inc Stock Price, News & Analysis

Oncolytics Biotech has announced that its partner, Adlai Nortye, has reached the third and final dose escalation cohort in the Chinese bridging trial for pelareorep in combination with paclitaxel, aimed at advanced breast cancer. The first two cohorts showed good tolerability with no new safety signals. This trial aligns with Oncolytics' North American studies and aims to facilitate regulatory submissions in key Asian markets, including China and Hong Kong. Significant survival benefits were noted from previous trials, furthering the potential for pelareorep's approval.

Oncolytics Biotech Inc. (NASDAQ: ONCY) announced the publication of preclinical and patient data on pelareorep in Immunology. The study highlights pelareorep's effects on Natural Killer (NK) cells and their activation, which is crucial for anti-cancer immunity. Results showed enhanced NK cell activity in patients with colorectal liver metastases after pelareorep treatment, mediated by type 1 interferon signaling. Going forward, Oncolytics aims to leverage these findings to further develop pelareorep in oncology, particularly for breast cancer and other indications.

Oncolytics Biotech announced promising phase 1b trial results for pelareorep combined with a proteasome inhibitor, achieving over three years of progression-free survival in relapsed/refractory multiple myeloma patients. Notable findings include increased tumor-infiltrating immune cells correlating with better clinical outcomes. The results will be presented at the AACR Annual Meeting on April 13, 2022. The company is advancing two ongoing phase 1 trials of pelareorep, collaborating with the National Cancer Institute and Bristol Myers Squibb for further evaluations.

Oncolytics Biotech (NASDAQ: ONCY) announced a poster presentation featuring long-term follow-up results from the ReoGlio phase 1b trial. This trial evaluates the combination of pelareorep and GM-CSF alongside standard chemoradiotherapy and temozolomide for glioblastoma multiforme (GBM) treatment. The presentation will occur at the AACR Annual Meeting 2022 in New Orleans, from April 8-13. The company is focusing on the efficacy of pelareorep as an immunotherapeutic agent and its potential synergies with other oncology treatments.

Oncolytics Biotech announced progress in its clinical trials and a strong financial position with approximately $41.3 million in cash. The BRACELET-1 trial for metastatic breast cancer is on track for top-line data in Q4 2022. Changes in T cell populations may serve as a predictive biomarker for therapy response, potentially reducing risk for further trials. Interim safety updates from ongoing trials indicate a favorable safety profile for pelareorep combinations. The net loss for 2021 was $26.3 million, showing improvement compared to $22.5 million in 2020.

Oncolytics Biotech (NASDAQ: ONCY) has scheduled a conference call and webcast for March 3, 2022, at 5:00 p.m. ET to review its fourth quarter and full year 2021 financial results. The company is advancing pelareorep, an immunotherapeutic agent aimed at treating various cancers by inducing anti-cancer immune responses. Ongoing and planned clinical trials are underway, including studies evaluating pelareorep in combination with checkpoint inhibitors. The investor relations page will host the webcast, available for three months.

Oncolytics Biotech announced the successful completion of the safety run-in for the pancreatic cancer cohort of the phase 1/2 GOBLET study, with no toxicity concerns reported by the Data Safety Monitoring Board. The study explores the efficacy of pelareorep in combination with Roche's checkpoint inhibitor, atezolizumab, for treating metastatic pancreatic, colorectal, and anal cancers. This evaluation adds to previous data showcasing pelareorep's potential to improve clinical responses by reversing immunosuppressive environments. The study is set to enroll patients at 14 sites in Germany.

Oncolytics Biotech Inc. (NASDAQ: ONCY) announced the completion of enrollment in the first dose escalation of a clinical trial evaluating pelareorep combined with paclitaxel for advanced breast cancer in China. There have been no reported safety issues, and the trial is progressing to its second cohort, which mirrors an earlier study showing improved survival rates. Results from this trial could facilitate future regulatory submissions in China, enhancing pelareorep's market potential in one of the largest pharmaceutical markets.

Oncolytics Biotech (NASDAQ: ONCY) updated on the phase 1/2 GOBLET study for pelareorep presented at the 2022 ASCO-GI symposium. The study evaluates pelareorep combined with Roche's atezolizumab in treating metastatic pancreatic, colorectal, and anal cancers. Enrollment for safety run-ins is complete at 14 sites in Germany. Prior studies suggest pelareorep may enhance responses to immune checkpoint inhibitors in GI cancers. The study aims to validate pelareorep's efficacy and identify potential biomarkers for patient selection.